Rachel Salazar, DHSc

Dr. Rachel Salazar is a biopharmaceutical executive and strategic advisor with more than 25 years of experience spanning research, drug development, portfolio strategy, organizational transformation, and enterprise-level innovation. She has held senior leadership roles across multiple global companies and partnered closely with Boards and executive teams to advance clinically meaningful medicines. As a healthcare leader, she brings a distinctive perspective on the critical role of physician leadership in shaping the future of patient-centered care.

In the biopharma sector, Rachel has led complex global programs and high-value portfolios at Bicara Therapeutics, EMD Serono, Takeda, and Pfizer. She has guided assets across the full development lifecycle and championed patient-centered strategies in collaboration with academic and government institutions, including the National Cancer Institute. Her leadership includes designing and implementing new operating models, strengthening portfolio discipline, and elevating scientific and operational performance across organizations.

During her career, she played a key role in support of building an oncology-focused biotechnology company from Series B through its 2024 IPO and transition to a publicly traded enterprise. She has extensive experience evaluating scientific, clinical, and commercial opportunities and integrating innovation into corporate strategy.

As HMD’s Life Sciences, Clinical Innovation & Strategy Board Advisor, Rachel is committed to bridging life sciences, drug development, clinical innovation, and healthcare strategy within physician leadership education. She brings scientific rigor, strategic clarity, and an enterprise-level lens to the organization’s assessment of opportunities for collaboration with the life sciences sector.

Rachel holds a Doctor of Health Science from Old Dominion University–Eastern Virginia Medical School, an MS in Biomedical Engineering from Tufts University, and a BS in Biomedical Engineering from Washington University in St. Louis. She also holds certifications in Regulatory Affairs, Strategy & Innovation, and Venture Finance, reflecting her multidisciplinary expertise across science, regulation, and business strategy.